Professional Documents
Culture Documents
(Download PDF) Nanomedicines Design Delivery and Detection Martin Braddock Online Ebook All Chapter PDF
(Download PDF) Nanomedicines Design Delivery and Detection Martin Braddock Online Ebook All Chapter PDF
https://textbookfull.com/product/adeno-associated-virus-vectors-
design-and-delivery-michael-j-castle/
https://textbookfull.com/product/animism-in-art-and-
performance-1st-edition-christopher-braddock-eds/
https://textbookfull.com/product/functional-design-principles-
patterns-and-practices-robert-c-martin-series-1st-edition-robert-
c-martin/
https://textbookfull.com/product/market-design-a-linear-
programming-approach-to-auctions-and-matching-martin-bichler/
Nanomaterials for Clinical Applications: Case Studies
in Nanomedicines (Micro and Nano Technologies) 1st
Edition Costas Demetzos (Editor)
https://textbookfull.com/product/nanomaterials-for-clinical-
applications-case-studies-in-nanomedicines-micro-and-nano-
technologies-1st-edition-costas-demetzos-editor/
https://textbookfull.com/product/design-synthesis-
multifunctionalization-and-biomedical-applications-of-
multifunctional-mesoporous-silica-based-drug-delivery-
nanosystems-1st-edition-yu-chen-auth/
https://textbookfull.com/product/measurement-and-detection-of-
radiation-third-edition-press/
Published on 31 March 2016 on http://pubs.rsc.org | doi:10.1039/9781782622536-FP001
Nanomedicines
Design, Delivery and Detection
View Online
Editor-in-Chief:
Professor David Thurston, King’s College, London, UK
Published on 31 March 2016 on http://pubs.rsc.org | doi:10.1039/9781782622536-FP001
Series Editors:
Professor David Rotella, Montclair State University, USA
Professor Ana Martinez, Centro de Investigaciones Biologicas-CSIC, Madrid,
Spain
Dr David Fox, Vulpine Science and Learning, UK
Nanomedicines
Design, Delivery and Detection
Published on 31 March 2016 on http://pubs.rsc.org | doi:10.1039/9781782622536-FP001
Edited by
Martin Braddock
AstraZeneca Research and Development, Macclesfield, UK
Email: martin.braddock@astrazeneca.com
Published on 31 March 2016 on http://pubs.rsc.org | doi:10.1039/9781782622536-FP001 View Online
A catalogue record for this book is available from the British Library
Apart from fair dealing for the purposes of research for non-commercial purposes or for
private study, criticism or review, as permitted under the Copyright, Designs and Patents
Act 1988 and the Copyright and Related Rights Regulations 2003, this publication may not
be reproduced, stored or transmitted, in any form or by any means, without the prior
permission in writing of The Royal Society of Chemistry or the copyright owner, or in the
case of reproduction in accordance with the terms of licences issued by the Copyright
Licensing Agency in the UK, or in accordance with the terms of the licences issued by the
appropriate Reproduction Rights Organization outside the UK. Enquiries concerning
reproduction outside the terms stated here should be sent to The Royal Society of
Chemistry at the address printed on this page.
The RSC is not responsible for individual opinions expressed in this work.
The authors have sought to locate owners of all reproduced material not in their own
possession and trust that no copyrights have been inadvertently infringed.
Printed in the United Kingdom by CPI Group (UK) Ltd, Croydon, CR0 4YY, UK
Published on 31 March 2016 on http://pubs.rsc.org | doi:10.1039/9781782622536-FP007
Preface
vii
View Online
viii Preface
the regulatory path and some of the promises and challenges which face us
today, together with an overview of the development of Doxils, the lessons
we have learnt from an integrated understanding of many disciplines and
the continued science in discovery today.
Looking further to the future; what may we envisage? It is inevitable that
as science progresses and more clinical trials complete, the true potential of
nanomedicine will be better understood. Advances in tumour targeting and
imaging continue to be made5 and the first human clinical trial assessing
the safety of ‘‘C dots’’, referred to in Chapter 5, has been completed6 with
further studies under way. Improvements in construct design continue to be
made and the potential utility of functionalized nanoparticles for drug de-
livery to the brain and neurodegenerative diseases is an emerging area.7,8
At the end of this journey, if the reader has acquired a good working
knowledge of the field, and is able to use this book as a reference and is
inquisitive enough to explore the field further, we will have achieved our
ambition.
Martin Braddock
References
1. R. P. Feynman, Eng. Sci., 1960, 23, 22.
2. M. S. Ventola, Pharm. Ther., 2012, 37, 582.
3. G. Pillai, SOJ Pharm. Pharm. Sci., 2014, 1, 13.
4. A. J. Balakrishnan, Nanomed. Res., 2014, 1, 12.
5. G. Lin, X. Wang, F. Yin and K.-T. Yong, Int. J. Nanomed., 2015, 10, 335.
6. E. Phillips, O. Penate-Medina, P. B. Zanzonica, R. D. Carvajal, P. Mohan,
Y. Ye, J. Humm, M. Gönen, H. Kalaigian, H. Schöder, W. H. Strauss,
S. M. Larson, U. Wiesner and M. S. Bradbury, Sci. Transl. Med., 2014,
6, 260ra149.
7. C.-T. Lu, Y.-Z. Zhao, H. L. Wong, J. Cai, L. Peng and X.-Q. Tian, Int. J.
Nanomed., 2014, 9, 2241.
8. G. Tosi, M. A. Vandelli, F. Forni and B. Ruozi, Exp. Opin. Drug Delivery,
2015, 12, 1041.
Published on 31 March 2016 on http://pubs.rsc.org | doi:10.1039/9781782622536-FP009
Contents
1.1 Introduction 1
1.2 Types of Nanocarriers/Nanoparticles 2
1.2.1 Viral Nanoparticles (VNPs) 2
1.2.2 Micelles and Liposomes 2
1.2.3 Polymeric Nanoparticles 4
1.2.4 Dendritic Nanoparticles 5
1.2.5 Peptidic Nanoparticles 6
1.2.6 Nanocrystals and Nanosuspensions 7
1.2.7 Metallic Nanoparticles 7
1.2.8 Silica Nanoparticles 8
1.2.9 Carbon-based Nanoparticles 8
1.3 Physicochemical Factors that Affect Nanoparticle
Efficiency 8
1.3.1 Size 10
1.3.2 Shape 11
1.3.3 Surface Charge 11
1.3.4 Ligands 12
1.4 Conclusions 13
References 14
ix
View Online
x Contents
2.1 Introduction 23
2.2 The Cell Cycle 24
2.2.1 An Overview 24
2.2.2 Restriction Points and Checkpoints 26
2.2.3 Regulation of Cell Cycle 27
2.3 Deregulation of the Cell Cycle in Cancer 28
2.3.1 Conventional Drug Therapy Against Cyclins
and CDK Inhibitors 29
2.4 RNA Interference 29
2.4.1 Mechanism of Action 29
2.4.2 RNAi and Cell Cycle Proteins 30
2.4.3 Overcoming RNAi Intended for Cell Cycle
Regulation 36
2.5 Concluding Remarks 38
Acknowledgements 39
References 39
3.1 Introduction 46
3.1.1 In Vitro siRNA Delivery 48
3.1.2 In Vivo siRNA Delivery 66
3.2 Extracellular Barriers 66
3.2.1 Surviving Degradation in the Systemic
Circulation 68
3.2.2 Escaping the Immune System 69
3.2.3 Exiting the Systemic Circulation at the
Site of Action 70
3.2.4 Extracellular Matrix 73
3.3 Cellular Barriers 74
3.3.1 Binding to the Cell Membrane 74
3.3.2 Entering the Cell 77
3.3.3 Permeating the Lipid Bilayer of
Endosomes 78
3.3.4 Intra-cytoplasmic Trafficking 79
View Online
Contents xi
Delivery 85
References 90
xii Contents
Contents xiii
xiv Contents
Contents xv
CHAPTER 1
1.1 Introduction
Delivery of drugs or genetic material into cells is one of the emerging areas of
biotechnology.1 Nanoparticle (NP)-based drug carriers are especially inter-
esting, due to their ability to deliver drugs inside target cells, thereby
reducing the side-effects of non-specific treatments.2 Among the various
cargoes that are transportable by NPs, genetic material allows the re-
programming of cells both temporarily as well as permanently.3 Several
approaches are available for gene delivery, such as the use of natural vectors,
like modified viruses, or artificial vectors, in the form of liposomes or pep-
tidic complexes. Among the key considerations for designing NPs to effect-
ively overcome biological barriers are their physicochemical properties and
effects they produce in the living organism. This chapter discusses how the
1
View Online
many types of cancers (breast, ovary, endometrium, kidney, lung, head and
neck, brain, and myeloid) and is internalized into cells after ligand bind-
ing.34 Another common strategy for the modification of NPs is the attach-
ment of peptidic sequences, which can help with the improvement of
translocation and absorption properties such as gastric mucoadhesiv-
Published on 31 March 2016 on http://pubs.rsc.org | doi:10.1039/9781782622536-00001
1.4 Conclusions
The nano-technological approach to improve gene/drug delivery has been a
dynamic and promising research field for a few decades. In the design of
nanocarriers, the intrinsic properties of NPs to select their composition for
controlled release of cargo. Therefore, one of the main functions of NPs
must be to serve as a transport system without increasing endogenous
toxicity of the transported substance (Figure 1.3). The different NPs de-
scribed in this chapter present advantages and drawbacks depending on the
application and route of administration (Table 1.1). Since NPs represent the
maximization of surface by unit of mass, improvement of the transporting
capacities of NPs can be performed by functionalization of their surface
(Table 1.2). NPs administered systemically tend to accumulate in tumors due
to the enhanced permeability and retention effect.28,173 Nevertheless, NPs
Another random document with
no related content on Scribd:
concessions. The late Sultan, as also the present, found that when they had not
accepted my disinterested advice, troubles ensued and they paid dearly. I
therefore still hold my ground at the Court, though Morocco has found itself on
more than one occasion, as in the last Spanish war, abandoned by England.
On the journey from Tangier to Fas, about three days’ march from
the former place, the Mission passed through the town of El Ksar,
near which is the famous battle-field where the Portuguese King,
Don Sebastian, was killed in 1578. In connection with this battle Sir
John wrote the following story.